Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevelamer + calcium acetate
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
This entry refers to a clinical study context conducted by the Gulhane School of Medicine comparing two distinct phosphate binders, sevelamer and calcium acetate, in patients with stage 4 chronic kidney disease (CKD) and hyperphosphatemia. Sevelamer is a non-calcium-based polymeric anion exchange resin, while calcium acetate is a calcium-based binder. The trial specifically investigated their respective impacts on serum fetuin-A levels and endothelial function (measured via flow-mediated dilation). The study found that sevelamer treatment significantly increased fetuin-A concentrations and improved endothelial dysfunction, whereas calcium acetate did not show these effects. Both medications are established therapies that work by binding dietary phosphate in the gastrointestinal tract to reduce systemic absorption, but they differ in their calcium content and potential pleiotropic effects on vascular health.
- Brand names
- RenagelRenvelaPhos-exPhosLoEliphos
- Other names
- sevelamer and calcium acetate
02
Targets
Pi (Inorganic phosphate)
Beyond the preview
Go deeper on sevelamer + calcium acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevelamer + calcium acetate.